Zafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity. It is also evaluating additional MetAP2 inhibitors beyond Beloranib as a development candidate for the treatment of severe obesity in the general population.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ZFGN
- CUSIP: N/A
- Web: www.zafgen.com
Capitalization:- Market Cap: $92.07 million
- Outstanding Shares: 27,483,000
Average Prices:- 50 Day Moving Avg: $3.46
- 200 Day Moving Avg: $3.97
- 52 Week Range: $2.89 - $5.46
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.39
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $3.63 per share
- Price / Book: 0.91
Profitability:- EBIDTA: ($50,510,000.00)
- Return on Equity: -44.54%
- Return on Assets: -40.97%
Debt:- Current Ratio: 11.72%
- Quick Ratio: 11.72%
Misc:- Average Volume: 166,648 shs.
- Beta: -1.36
- Short Ratio: 2.51
Frequently Asked Questions for Zafgen (NASDAQ:ZFGN)
What is Zafgen's stock symbol?
Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."
How were Zafgen's earnings last quarter?
Zafgen, Inc. (NASDAQ:ZFGN) posted its earnings results on Tuesday, August, 8th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.03. During the same period in the previous year, the business posted ($0.55) earnings per share. View Zafgen's Earnings History.
When will Zafgen make its next earnings announcement?
Where is Zafgen's stock going? Where will Zafgen's stock price be in 2017?
2 analysts have issued 1-year target prices for Zafgen's shares. Their predictions range from $9.00 to $9.00. On average, they anticipate Zafgen's stock price to reach $9.00 in the next twelve months. View Analyst Ratings for Zafgen.
Who are some of Zafgen's key competitors?
Some companies that are related to Zafgen include Aileron Therapeutics (ALRN), Vascular Biogenics (VBLT), Threshold Pharmaceuticals (MTEM), Conatus Pharmaceuticals (CNAT), Cempra (CEMP), Fate Therapeutics (FATE), XBiotech (XBIT), Recro Pharma (REPH), Summit Therapeutics PLC (SMMT), Redhill Biopharma (RDHL), Synthetic Biologics (SYN), Cellular Biomedicine Group (CBMG), Adverum Biotechnologies (ADVM), Trevena (TRVN), Dimension Therapeutics (DMTX), AcelRx Pharmaceuticals (ACRX), ProQR Therapeutics N.V. (PRQR) and Aldeyra Therapeutics (ALDX).
Who are Zafgen's key executives?
Zafgen's management team includes the folowing people:
- Peter Barrett Ph.D., Independent Chairman of the Board
- Thomas E. Hughes Ph.D., President, Chief Executive Officer, Director
- Patricia L. Allen CPA, Chief Financial Officer
- Dennis D. Kim M.D., Chief Medical Officer
- Bruce L. Booth Ph.D., Director
- Thomas O. Daniel M.D., Director
- Geoffrey McDonough M.D., Director
- Robert J. Perez, Director
- Frances K. Heller J.D., Independent Director
Who owns Zafgen stock?
Zafgen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.87%), Artal Group S.A. (3.65%), Vanguard Group Inc. (3.23%), Dimensional Fund Advisors LP (2.13%), Royce & Associates LP (1.21%) and Spark Investment Management LLC (1.03%). Company insiders that own Zafgen stock include Dennis D Kim, Frances K Heller, James E Flynn, Kevin P Starr, Patricia L Allen and Thomas E Hughes. View Institutional Ownership Trends for Zafgen.
Who sold Zafgen stock? Who is selling Zafgen stock?
Zafgen's stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, TIAA CREF Investment Management LLC, Bank of New York Mellon Corp, Royce & Associates LP, Candriam Luxembourg S.C.A. and Royal Bank of Canada. View Insider Buying and Selling for Zafgen.
Who bought Zafgen stock? Who is buying Zafgen stock?
Zafgen's stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Vanguard Group Inc., OxFORD Asset Management LLP, Spark Investment Management LLC, Acadian Asset Management LLC, LMR Partners LLP and GSA Capital Partners LLP. Company insiders that have bought Zafgen stock in the last two years include Dennis D Kim, Frances K Heller, James E Flynn, Patricia L Allen and Thomas E Hughes. View Insider Buying and Selling for Zafgen.
How do I buy Zafgen stock?
Shares of Zafgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zafgen's stock price today?
One share of Zafgen stock can currently be purchased for approximately $3.32.
MarketBeat Community Rating for Zafgen (NASDAQ ZFGN)MarketBeat's community ratings are surveys of what our community members think about Zafgen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Zafgen (NASDAQ:ZFGN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 1 Buy Rating |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $9.00 (171.08% upside) |
Analysts' Ratings History for Zafgen (NASDAQ:ZFGN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 4/20/2017 | Roth Capital | Initiated Coverage | Buy -> Buy | $9.00 | High |  |
| 3/10/2017 | Cowen and Company | Reiterated Rating | Hold | | N/A | |
| 3/7/2017 | FBR & Co | Reiterated Rating | Marketperform | | Low | |
| 7/21/2016 | Canaccord Genuity | Set Price Target | Hold | $7.00 -> $4.00 | N/A | |
| 7/20/2016 | Leerink Swann | Reiterated Rating | Market Perform | $6.00 | N/A | |
| 4/5/2016 | Royal Bank Of Canada | Reiterated Rating | Outperform | $19.00 | N/A | |
| 2/20/2016 | SunTrust Banks, Inc. | Reiterated Rating | Hold | $7.00 | N/A | |
| 10/16/2015 | JMP Securities | Downgrade | Outperform -> Market Perform | | N/A | |
(Data available from 9/22/2015 forward)
Earnings History for Zafgen (NASDAQ:ZFGN)Earnings History by Quarter for Zafgen (NASDAQ ZFGN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($0.58) | | | | | N/A | |
| 8/8/2017 | Q2 2017 | ($0.52) | ($0.49) | | | View | Listen | |
| 5/9/2017 | Q1 2017 | ($0.43) | ($0.48) | | | View | N/A | |
| 3/9/2017 | Q4 2016 | ($0.50) | ($0.38) | | | View | Listen | |
| 5/10/2016 | Q116 | ($0.74) | ($0.65) | | | View | Listen | |
| 3/9/2016 | Q415 | ($0.80) | ($0.85) | | | View | N/A | |
| 11/10/2015 | Q3 | ($0.79) | ($0.73) | $80.60 million | $78.20 million | View | Listen | |
| 8/11/2015 | Q215 | ($0.71) | ($0.66) | | | View | Listen | |
| 5/12/2015 | Q115 | ($0.52) | ($0.53) | | | View | Listen | |
| 3/19/2015 | Q414 | ($0.84) | ($0.48) | | | View | Listen | |
| 11/11/2014 | Q314 | ($0.87) | ($0.65) | | | View | N/A | |
| 8/13/2014 | Q214 | ($0.28) | ($2.96) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Zafgen (NASDAQ:ZFGN)2017 EPS Consensus Estimate: ($2.24)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.49) | ($0.41) | ($0.45) |
| Q2 2017 | 2 | ($0.58) | ($0.53) | ($0.56) |
| Q3 2017 | 2 | ($0.64) | ($0.54) | ($0.59) |
| Q4 2017 | 2 | ($0.70) | ($0.59) | ($0.65) |
(Data provided by Zacks Investment Research)
Dividend History for Zafgen (NASDAQ:ZFGN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Zafgen (NASDAQ:ZFGN)Insider Ownership Percentage: 21.20%
Institutional Ownership Percentage: 48.52%
Insider Trades by Quarter for Zafgen (NASDAQ:ZFGN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/11/2017 | Dennis D Kim | Insider | Buy | 10,000 | $3.39 | $33,900.00 | |
| 5/11/2017 | Dennis D. Kim | Insider | Buy | 10,000 | $4.40 | $44,000.00 | |
| 12/19/2016 | Frances K Heller | Director | Buy | 10,000 | $3.23 | $32,300.00 | |
| 11/15/2016 | Frances K Heller | Director | Buy | 10,000 | $3.54 | $35,400.00 | |
| 8/29/2016 | Thomas E Hughes | Insider | Buy | 10,000 | $3.00 | $30,000.00 | |
| 7/26/2016 | Patricia L. Allen | CFO | Buy | 16,000 | $3.12 | $49,920.00 | |
| 7/22/2016 | Frances K Heller | Director | Buy | 10,000 | $2.99 | $29,900.00 | |
| 7/22/2016 | Thomas E. Hughes | Insider | Buy | 5,000 | $3.02 | $15,100.00 | |
| 2/12/2016 | James E Flynn | Insider | Buy | 64,545 | $6.25 | $403,406.25 | |
| 2/11/2016 | James E Flynn | Insider | Buy | 267,493 | $6.02 | $1,610,307.86 | |
| 9/24/2015 | Kevin P Starr | Director | Sell | 136,579 | $43.90 | $5,995,818.10 | |
| 9/18/2015 | Avi Y Goldberg | Director | Sell | 5,000 | $45.00 | $225,000.00 | |
| 9/18/2015 | Thomas E. Hughes | CEO | Sell | 45,626 | $42.53 | $1,940,473.78 | |
| 9/17/2015 | Dennis D. Kim | insider | Sell | 39,407 | $40.00 | $1,576,280.00 | |
| 6/10/2015 | Avi Y Goldberg | Director | Sell | 3,000 | $35.00 | $105,000.00 | |
| 6/1/2015 | Avi Y Goldberg | Director | Sell | 2,000 | $32.23 | $64,460.00 | |
| 6/19/2014 | Alicia Secor | Insider | Buy | 4,000 | $20.00 | $80,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Zafgen (NASDAQ:ZFGN)
Latest Headlines for Zafgen (NASDAQ:ZFGN)
| Source: |
|
| Date | Headline |
|---|
 | Zafgen, Inc. (ZFGN) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - September 19 at 11:24 AM |
| Zafgen, Inc. (ZFGN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - September 15 at 6:46 PM |
 | Zafgen (ZFGN) Starts Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes
www.streetinsider.com - September 14 at 12:06 PM |
| Zafgen, Inc. (ZFGN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - September 13 at 12:26 PM |
| Zafgen (ZFGN) Starts Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes - StreetInsider.com
www.streetinsider.com - September 13 at 1:42 AM |
 | Zafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes
finance.yahoo.com - September 12 at 8:41 PM |
| Zafgen (ZFGN) Announces New Preclinical Data on ZGN-1061 - StreetInsider.com
www.streetinsider.com - September 12 at 12:38 PM |
| Zafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of Diabetes
finance.yahoo.com - September 12 at 12:38 PM |
| Zafgen, Inc. (ZFGN) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - September 9 at 12:34 PM |
| Zafgen, Inc. (ZFGN) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 6 at 5:16 PM |
| Zafgen, Inc. (ZFGN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - September 1 at 12:22 PM |
| Zafgen, Inc. (ZFGN) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - August 30 at 6:16 PM |
| Zafgen, Inc. (ZFGN) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - August 26 at 10:12 AM |
| Zacks: Brokerages Anticipate Zafgen, Inc. (ZFGN) to Post -$0.54 EPS
www.americanbankingnews.com - August 21 at 10:20 PM |
| Zafgen, Inc. (NASDAQ:ZFGN) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 12 at 5:02 PM |
| Zafgen, Inc. (NASDAQ:ZFGN) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - August 12 at 10:00 AM |
| Q3 2017 EPS Estimates for Zafgen, Inc. Increased by Leerink Swann (ZFGN)
www.americanbankingnews.com - August 11 at 7:48 AM |
| Zafgen, Inc. (ZFGN) Releases Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - August 10 at 3:22 PM |
 | Zafgen Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 9 at 3:29 PM |
| Investor Network: Zafgen, Inc. to Host Earnings Call
finance.yahoo.com - August 9 at 9:28 AM |
| Zafgen Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 9:28 AM |
| Zafgen reports 2Q loss
finance.yahoo.com - August 9 at 9:28 AM |
| Zafgen to Present at the Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 3 at 9:13 AM |
| Zafgen to Host Conference Call to Discuss Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 9:03 AM |
| Zafgen, Inc. (ZFGN) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:45 AM |
| Zafgen, Inc. (NASDAQ:ZFGN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 18 at 5:31 PM |
| Zafgen, Inc. (NASDAQ:ZFGN) Short Interest Update
www.americanbankingnews.com - July 16 at 7:14 AM |
 | BUZZ-US STOCKS ON THE MOVE- Yandex, US Retailers, Teva, Tesaro - Nasdaq
www.nasdaq.com - July 13 at 3:33 PM |
| Zacks Investment Research Lowers Zafgen, Inc. (ZFGN) to Hold
www.americanbankingnews.com - July 13 at 3:02 PM |
| Dennis D. Kim Acquires 10,000 Shares of Zafgen, Inc. (NASDAQ:ZFGN) Stock
www.americanbankingnews.com - July 12 at 8:45 PM |
| Zacks: Brokerages Expect Zafgen, Inc. (ZFGN) to Post -$0.53 Earnings Per Share
www.americanbankingnews.com - July 12 at 12:56 PM |
| Zafgen, Inc. (ZFGN) Lifted to Sell at ValuEngine
www.americanbankingnews.com - July 8 at 2:20 PM |
| Zafgen, Inc. (NASDAQ:ZFGN) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - July 8 at 9:10 AM |
| Zafgen, Inc. (ZFGN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - June 23 at 2:50 PM |
| Analysts Anticipate Zafgen, Inc. (ZFGN) to Announce -$0.56 Earnings Per Share
www.americanbankingnews.com - June 16 at 12:32 PM |
| Zafgen to Present at the JMP Securities Life Sciences Conference - GlobeNewswire (press release)
globenewswire.com - June 14 at 4:30 PM |
| Zafgen to Present at the JMP Securities Life Sciences Conference
finance.yahoo.com - June 14 at 2:29 AM |
| Zafgen (ZFGN) Announces New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes & Obesity - StreetInsider.com
www.streetinsider.com - June 12 at 6:27 AM |
| Zafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at the American Diabetes Association’s 77th Annual Scientific Sessions
finance.yahoo.com - June 11 at 8:22 AM |
| Zafgen to Present Two Late-Breaking Abstracts for ZGN-1061 at the American Diabetes Association 77th Scientific Sessions
finance.yahoo.com - June 7 at 1:30 AM |
| Zafgen Inc (ZFGN) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - June 2 at 5:42 PM |
| Zafgen Inc (ZFGN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 29 at 2:58 PM |
| Zafgen Inc (ZFGN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 13 at 9:04 AM |
| FY2017 EPS Estimates for Zafgen Inc (ZFGN) Raised by Leerink Swann
www.americanbankingnews.com - May 12 at 11:44 AM |
| FY2017 Earnings Estimate for Zafgen Inc Issued By SunTrust Banks (ZFGN)
www.americanbankingnews.com - May 12 at 11:44 AM |
| Insider Buying: Zafgen Inc (ZFGN) Insider Purchases 10,000 Shares of Stock
www.americanbankingnews.com - May 11 at 8:48 PM |
| Zafgen Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - May 11 at 8:26 PM |
 | Zafgen's Second Act
seekingalpha.com - May 11 at 3:25 PM |
| Zafgen Inc (ZFGN) Issues Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - May 10 at 5:22 PM |
| Zafgen Inc (ZFGN) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - May 10 at 11:40 AM |
Zafgen (ZFGN) Chart for Friday, September, 22, 2017
